The 29th  International Symposium on Hepatitis C Virus, Flaviviruses, and Related Viruses will be organized from 1 to 5 October 2023 at theJW Marriot in Atlanta, Georgia, USA

While historically this  meeting was predominantly focused on  HCV, we now have expanded its scope to completely  embrace  flavivirologists into our community. Hence the slight name-change of the meeting

Do you want to share and  discuss your latest research and  discoveries on hepatitis C virus, Dengue  virus, Yellow fever virus,  West Nile virus, Pestiviruses, enteric hepatitis  viruses, …?

Submit your abstract for an oral and/or poster presentation on the following topics:

• viral entry, replication, translation and assembly

• pathogenesis

• in vitro and in vivo models

• innate and adaptive immunity

• vaccine development

• epidemiology and diagnosis

• antiviral therapy and resistance

• elimination

Topics

Your abstract must be submitted under a specific topic so that it will be reviewed in the appropriate category. Choose the topic that fits best with the content of your work. In case of doubt indicate a second topic that may also be relevant. The scientific committee may decide to allocate your abstract to a different topic than the one indicated by the submitting author in case that would facilitate the reviewing process. Authors will not be penalized if their abstract is transferred to another category.

The following topics can be selected:

• viral entry

• replication and translation

• assembly

• pathogenesis

• in vitro and in vivo models

• innate immunity

• adaptive immunity

• vaccine development

• epidemiology and diagnosis

• antiviral therapy and resistance

• elimination

Abstract Body

Abstract should be submitted on an MS WORD document. The abstract content should not exceed 2.500 characters (excluding spaces) and should be structurally organized in the following sub-sections:

• Authors list: the presenting author and all co-authors with affiliations

• Background and Aims:

• Methods:

• Results:

• Conclusions:

• Figure/Image/Table: limited to one figure OR one image OR one table per abstract

The following additional rules apply to the abstract body:

• The abstract should be submitted in English only. The use of correct   English is essential. Authors are responsible for proofreading and  submitting  an abstract without errors, as it will be reproduced in the  form it was submitted.

• Abbreviations can be used in the abstract body, provided they are  defined at first usage.

• Main formatting rules:

  • Font type ‘Arial’ ; Font size 11

  • Decimal point should be a comma (2,5)

  • Use a period as thousand separator (2.500,00)

  • Put spaces between signs and number (2,5 = a)

  • Significance value should be small ‘p’, not bolded nor italic

  • Avoid using symbols (use “alpha”, not a). Never use the “symbol” font

Types of sessions for accepted abstracts

Your abstract, if accepted,  will fall under one of the following presentation types:

• oral presentation (12  minutes presentation, followed by 3 minutes of discussion)

• poster presentation

Please  indicate your preference of the presentation type (oral, poster, or both) 		

Young investigators

If you are still in  training, you can apply for a travel bursary  and/or student housing (based on  availability). Trainee level is  defined as either a PhD student or a young  post-doc (first 4 years  after defense of PhD at abstract submission closure;  extensions may be  granted in case of maternity leave). Proof of trainee level  status  should be uploaded  together with your abstract submission.

Trainees are only eligible for  travel support if they are the  presenting author (i.e. 1st author on  the abstract). Young  investigators that submit an abstract as presenting author  will be  allowed to register at the early registration rate, even if the early   registration period has been closed. This will allow young investigators  to  register at preferential rates after they have been notified of  acceptance of  their abstract.

Abstract Title

The title should be on a single line (no paragraphs) and may not exceed 200 characters (excluding spaces). Do not use all capital letters and do not capitalize the first letter of each word. The title may not contain abbreviations. Do not put a period at the end of the title. The HCV-Flavi 2022 Scientific Committee reserves the right to correct the title format without further recourse to the authors.

Authors

The first author (= presenting author) is  responsible for the  abstract content and is the contact person for  communication purposes  and dissemination of information to co-authors. 

First author and co-authors need to provide  their full name  and affiliation (department (optional), institution/company,  city,  country).

Submission

• The abstract submission platform will remain open until 1 May 2022 and abstracts may be edited until this time, provided they are in ‘incomplete’ (Draft mode).

• To submit the abstract, each submitter needs to click “save and submit” at the last step to complete the process. Abstracts that are in “incomplete’ (Draft mode)” status after submission deadline will not be considered for revision.

• An abstract should be submitted only once, resubmission is not permitted.

• Each abstract submitter will be required to create an account at the submission platform.

• Abstracts will be checked for plagiarism and will be automatically rejected if plagiarism is identified.

Notification and Registration

First authors will be notified of acceptance  of their abstract on 23  May 2022.

  The first author (= presenting author) should  complete his/her registration for the HCV-Flavi 2022 Meeting by 30 April 2022  (early  bird fees guaranteed for young investigators only). Only use  the registration  link provided in your acceptance e-mail to register  for the HCV-Flavi 2022 Meeting.

If your full registration has not been  received by 30 April 2022,   your abstract/poster will no longer be considered. As the program  develops,  sessions may change, and your presentation may be placed in a  different session.  Please bear this in mind when making your  conference planning.

Withdrawal

If the first author wishes to withdraw the abstract from the HCV-Flavi 2022 Meeting after outcome notifications have been made available, he/she must submit a written request at the latest for 1 June 2022 to HCV-Flavi2022.abstracts@eventmasters.eu. Any abstract withdrawal requests made after this date cannot be assured of removal from the HCV-Flavi 2022 Abstract Book.

Publication

All accepted abstracts will be published online in the HCV-Flavi 2022 Abstract Book, but will be password protected and only be accessible to people who were registered for the meeting.